0001193125-21-031663.txt : 20210312 0001193125-21-031663.hdr.sgml : 20210312 20210208083358 ACCESSION NUMBER: 0001193125-21-031663 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20210208 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Talis Biomedical Corp CENTRAL INDEX KEY: 0001584751 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-433-3000 MAIL ADDRESS: STREET 1: 230 CONSTITUTION DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: SlipChip Corp DATE OF NAME CHANGE: 20130820 CORRESP 1 filename1.htm CORRESP

LOGO

 

Karen E. Deschaine

+1 858 550 6088

kdeschaine@cooley.com

    VIA EDGAR

February 8, 2021

United States Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 4720

100 F Street, N.E.

Washington, D.C. 20549

Attn: Jeffrey Gabor, Tim Buchmiller, Michael Fay, and Brian Cascio

 

Re:   

Talis Biomedical Corporation

Registration Statement on Form S-1

Filed January 22, 2021

File No. 333-252360

Dear Mr. Gabor:

On behalf of our client, Talis Biomedical Corporation (the “Company”), we are submitting this response letter in response to comments received from the staff (the “Staff”) of the Securities and Exchange Commission (the “Commission”) by letter dated January 29, 2021 (the “Comment Letter”) with respect to the Company’s Registration Statement on Form S-1 filed with the Commission on January 22, 2021 (the “Registration Statement”). We are also electronically transmitting for filing an Amendment No. 1 to the Registration Statement on Form S-1 (the “Amended Registration Statement”) that updates the Registration Statement.

The numbering of the paragraph below corresponds to the numbering in the Comment Letter, the text of which we have incorporated into this response letter for convenience. Except where otherwise indicated, page references in the text of the response below corresponds to the page numbers of the Amended Registration Statement.

Staff Comments and Company Responses to Comment Letter

Registration Statement on Form S-1 filed with the Commission on January 22, 2021

Talis One tests, page 126

 

  1.

We note your response to prior comment 2 and reissue. Please revise the Overview section of the Prospectus Summary to clearly disclose that your initial focus was on women’s health and sexually transmitted infections and that you postponed development of that program to focus on a COVID-19 test. Alternatively, tell us why this information does not warrant summary level disclosure.

Response:      The Company has updated the disclosures on page 5 of the Amended Registration Statement.

*        *         *

 

Cooley LLP     4401 Eastgate Mall     San Diego, CA     92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com

LOGO

United States Securities and Exchange Commission

February 8, 2021

Page Two

 

The Company respectfully requests the Staff’s assistance in completing the review of the Amended Registration Statement as soon as possible. Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding the Amended Registration Statement or this response letter to me at (858) 550-6088.

Sincerely,

Cooley LLP

/s/ Karen E. Deschaine

Karen E. Deschaine

 

cc:   

Brian Coe, Chief Executive Officer, Talis Biomedical Corporation

Brian J. Cuneo, Latham & Watkins LLP

 

Cooley LLP     4401 Eastgate Mall     San Diego, CA     92121

t: (858) 550-6000 f: (858) 550-6420 cooley.com

GRAPHIC 2 g25171g73u95.jpg GRAPHIC begin 644 g25171g73u95.jpg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